- Home
- SAVA vs SKWD Comparison
SAVA vs SKWD Comparison
Compare SAVA & SKWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- SKWD
- Stock Information
- Founded
- SAVA 1998
- SKWD 2007
- Country
- SAVA United States
- SKWD United States
- Employees
- SAVA N/A
- SKWD N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- SKWD Property-Casualty Insurers
- Sector
- SAVA Health Care
- SKWD Finance
- Exchange
- SAVA Nasdaq
- SKWD Nasdaq
- Market Cap
- SAVA 1.3B
- SKWD 1.5B
- IPO Year
- SAVA N/A
- SKWD 2023
- Fundamental
- Price
- SAVA $27.08
- SKWD $44.22
- Analyst Decision
- SAVA Buy
- SKWD Buy
- Analyst Count
- SAVA 3
- SKWD 10
- Target Price
- SAVA $107.00
- SKWD $44.25
- AVG Volume (30 Days)
- SAVA 1.9M
- SKWD 371.8K
- Earning Date
- SAVA 11-05-2024
- SKWD 11-04-2024
- Dividend Yield
- SAVA N/A
- SKWD N/A
- EPS Growth
- SAVA N/A
- SKWD 81.83
- EPS
- SAVA N/A
- SKWD 2.96
- Revenue
- SAVA N/A
- SKWD $1,030,428,000.00
- Revenue This Year
- SAVA N/A
- SKWD N/A
- Revenue Next Year
- SAVA N/A
- SKWD $12.96
- P/E Ratio
- SAVA N/A
- SKWD $14.73
- Revenue Growth
- SAVA N/A
- SKWD 38.14
- 52 Week Low
- SAVA $8.79
- SKWD $27.12
- 52 Week High
- SAVA $42.20
- SKWD $43.93
- Technical
- Relative Strength Index (RSI)
- SAVA 46.80
- SKWD 72.15
- Support Level
- SAVA $26.10
- SKWD $40.29
- Resistance Level
- SAVA $31.65
- SKWD $41.38
- Average True Range (ATR)
- SAVA 2.55
- SKWD 1.00
- MACD
- SAVA -0.50
- SKWD 0.22
- Stochastic Oscillator
- SAVA 15.08
- SKWD 99.20
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.